Alexandre Willaume

ORCID: 0000-0003-4194-4254
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Multiple Myeloma Research and Treatments
  • Cardiac tumors and thrombi
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Immune Cell Function and Interaction
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • CNS Lymphoma Diagnosis and Treatment
  • Hematological disorders and diagnostics
  • Acute Myeloid Leukemia Research
  • Protein Degradation and Inhibitors
  • Radiomics and Machine Learning in Medical Imaging
  • Fungal Infections and Studies
  • Neutropenia and Cancer Infections
  • Traumatic Brain Injury and Neurovascular Disturbances
  • Histone Deacetylase Inhibitors Research
  • Parasitic Infections and Diagnostics
  • Gastrointestinal Tumor Research and Treatment
  • Sepsis Diagnosis and Treatment
  • Research on Leishmaniasis Studies
  • CAR-T cell therapy research
  • Long-Term Effects of COVID-19
  • MRI in cancer diagnosis
  • Leprosy Research and Treatment
  • Medical Imaging Techniques and Applications

Université Catholique de Lille
2022-2024

Hôpital Saint-Vincent-de-Paul
2022-2024

Hôpital Claude Huriez
2020-2023

Centre Hospitalier Universitaire de Lille
2018-2023

Lille’s Cardiology Hospital
2021-2023

Groupe Hospitalier de l'Institut Catholique de Lille
2023

Université de Picardie Jules Verne
2020

Hématopoïèse et immunologie
2020

Université de Lille
2019

Abstract Primary mediastinal B-cell lymphoma (PMBL) is a rare type of aggressive typically affecting young female patients. The first-line standard care remains debated. We performed large multicenter retrospective study in 25 centers France and Belgium to describe PMBL patient outcomes after treatment real-life settings. A total 313 patients were enrolled received rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone) (n = 180) or CHOP (cyclophosphamide,...

10.1182/bloodadvances.2021004778 article EN cc-by-nc-nd Blood Advances 2021-08-30

Abstract The selenoprotein glutathione peroxidase 4 (GPX4), the only member of family able to directly reduce cell membrane–oxidized fatty acids and cholesterol, was recently identified as central regulator ferroptosis. GPX4 knockdown in mouse hematopoietic cells leads hemolytic anemia increased spleen erythroid progenitor death. role during human erythropoiesis is unknown. Using vitro differentiation, we show here that GPX4-irreversible inhibition by 1S,3R-RSL3 (RSL3) its short hairpin...

10.1182/bloodadvances.2020003100 article EN cc-by-nc-nd Blood Advances 2020-11-19

Abstract Primary mediastinal B-cell lymphoma (PMBL) is an uncommon entity of aggressive with unusually good prognosis, except for 10-15% chemotherapy-refractory cases. To identify earlier these higher risk patients, we performed molecular characterization a retrospective multicenter cohort patients treated firstline immunochemotherapy. The traits the gene-expression profiling data (n = 120) were as follows: median age 34 years (range, 18-67 years); female sex, 58.3%; elevated lactate...

10.1182/bloodadvances.2023011169 article EN cc-by-nc-nd Blood Advances 2023-10-20

The first-step in diagnosis of myelodysplastic neoplasms (MDS) is essentially based on bone marrow cytomorphology. However, cytomorphology MDS often a difficult exercise, subject to inter-operator variability. Our study aims evaluate whether the combination two dysplasia scores, extended Ogata score and MDS-CBC score, could improve screening patients among with chronic cytopenia.

10.1111/ijlh.14404 article EN cc-by-nc-nd International Journal of Laboratory Hematology 2024-12-10

Introduction: Primary mediastinal large B-cell lymphoma (PMBL) is a unique entity with an unusually good prognosis, except for ∼15% of refractory patients. Routine diagnosis relies on clinicopathological confrontation. Tools to detect earlier patients are lacking. Methods: We implemented biological characterization multicenter retrospective LYSA cohort that previously reported clinical outcomes 313 adult PMBL treated first-line ACVBP or CHOP plus anti-CD20 between 2007 and 2017. centrally...

10.1002/hon.3163_70 article EN Hematological Oncology 2023-06-01

Introduction: New prognostic factors have emerged such as total metabolic tumor volume (TMTV) assessed by PET-CT in large B cell lymphoma (DLBCL). Normal T, and NK cells are also involved antitumoral response. What is the impact of lymphopenia at time diagnosis on a population? Methods: We pooled 1095 patients from 3 LYSA studies (GAINED, RT3 REMARC) with TMTV Lymphocytes available. Results: The three differ for mean age diagnosis: GAINED were younger (median 48; IC: 18–61) than (66; 20–92)...

10.1002/hon.3164_248 article EN Hematological Oncology 2023-06-01

Introduction: Primary mediastinal B-cell lymphoma (PMBL) is a rare subtype of aggressive typically affecting young female patients. The first-line standard care remains debated. Methods: We performed large multicenter retrospective study in 25 centers France and Belgium to describe PMBL patient outcomes after treatment real-life settings. All adult patients with newly diagnosed treated by participating Lymphoma Study Association (LYSA) from 01/01/2007 31/12/2017 were identified local...

10.1002/hon.50_2879 article EN Hematological Oncology 2021-06-01
Coming Soon ...